Organogenesis Holdings Inc Revenue per Employee (ORGO), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Organogenesis Holdings Inc   (NASDAQ: ORGO)
 

Organogenesis Holdings Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Organogenesis Holdings Inc 's Revenue per employee fell on a trailing twelve month basis to $ 535,660, but the productivity of Organogenesis Holdings Inc 's employees remained above the company average.
Within the Healthcare sector Employees of 143 other companies have achieved higher revenue per employee. While Organogenesis Holdings Inc 's total ranking has deteriorated compared to the previous quarter from 1008 to 1375. Organogenesis Holdings Inc has 854 employees.


What is Sales per Employee Ratio?







ORGO Revenue per Employee (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Revenue Change -56.68 % -57.06 % 78.13 % 30.98 % -22.44 %
Sales per Employee (TTM) $ 535,660 602,698 660,619 544,752 502,964
ORGO's Total Ranking # 1375 # 1008 # 823 # 1480 # 1422
Seq. Revenue Change 17.53 % -83.5 % 49.54 % 49.36 % 16.51 %


Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 93
Healthcare Sector # 144
Overall Market # 1375

Revenue per Employee Statistics
High Average Low
$ 660,619 $ 440,671 $ 214,276
(Dec 31 2025)   (Sep 30 2018)



Financial Statements
Organogenesis Holdings Inc 's Revenue MRQ $ 44 Millions Visit ORGO's Income Statement
Organogenesis Holdings Inc 's Revenues TTM $ 457 Millions Visit ORGO's aggregate revenue growth
What are ORGO's Sales? Visit ORGO's Sales by Segment


  News about Organogenesis Holdings Inc Revenue per employee

Organogenesis Navigates Funding Gaps and Policy Shifts Amidst Record High Revenue: A Dual Focus on Growth and Patient-Centric Solutions

In an era where healthcare innovation is paramount, Organogenesis Holdings Inc. finds itself at a critical crossroads. As the company pushes for a delay in the Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD) implementation, it seeks to bolster its commitment to patient access and the strength of medical evidence supporting its treatments. However, this advocacy comes against the backdrop of a significant financial struggle that raises questions about the firm’s sustainability and future in a competitive landscape. A Shift in Coverage and Payment Policy Organogenesis, a company specializing in regenerative medicine, has advocated for “an integrated coverage and payment policy� as it endeavors to ensure that patients have access to its innovative therapies. The recent push for a delay in the LCD implementation underscores the company’s desire to review existing coverage policies more thoroughly. By requesting this postponement, Organogenesis aims to assure the healthcare system that its treatments not only meet regulatory standards but are also backed by substantial evidence of effectiveness.




Other Ratios
Organogenesis Holdings Inc 's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
ORGO's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for ORGO's Competitors
Revenue per Employee for ORGO's Suppliers
Revenue per Employee for ORGO's Customers

You may also want to know
ORGO's Sales Growth Rates ORGO's Pe Price to earnings ratio ORGO's Receivables Turnover Ratio ORGO's Stock Quote
ORGO's Net Income Growth Rates ORGO's Ps Price to Sales ratio ORGO's Sales per Employee ORGO's Asset Turnover Ratio
ORGO's Net Margin ORGO's Pb Price to Book ratio ORGO's Financial Strength Ratios ORGO's Dividend Payout Ratio
Date modified: 2026-09-26T07:31:38+00:00




Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Jun 30 2026Number of Employees Jun 30 2026
Scilex Holding Company  929,647.06 $ 31.608  Million 34 
Ardelyx inc   922,073.62 $ 450.894  Million 489 
The Oncology Institute Inc   916,137.29 $ 587.244  Million 641 
Pacira Biosciences inc   900,077.20 $ 746.164  Million 829 
Fortress Biotech Inc   897,217.95 $ 69.983  Million 78 
Alphatec Holdings Inc   892,420.59 $ 814.780  Million 913 
Merck and Co Inc   887,586.67 $ 66,569.000  Million 75,000 
Nektar Therapeutics  866,492.06 $ 54.589  Million 63 
Carlisle Companies Incorporated  863,898.31 $ 5,097.000  Million 5,900 
Verastem Inc   858,098.04 $ 87.526  Million 102 
Emergent Biosolutions Inc   855,777.78 $ 770.200  Million 900 
Bridgebio Pharma Inc   849,903.46 $ 713.069  Million 839 
Pfizer Inc  849,280.00 $ 63,696.000  Million 75,000 
Syndax Pharmaceuticals Inc   845,651.01 $ 252.004  Million 298 
Xilio Therapeutics Inc   843,315.79 $ 64.092  Million 76 
Axsome Therapeutics Inc   839,534.05 $ 776.569  Million 925 
Ionis Pharmaceuticals Inc   834,107.70 $ 1,169.419  Million 1,402 
Vir Biotechnology Inc   826,231.61 $ 303.227  Million 367 
Immunocore Holdings Plc  822,089.69 $ 430.775  Million 524 
Prothena Corporation Public Limited Company  813,880.60 $ 54.530  Million 67 
Alkermes Plc   813,488.78 $ 1,667.652  Million 2,050 
Lifevantage Corp  811,421.52 $ 180.947  Million 223 
Sanuwave Health Inc   798,236.36 $ 43.903  Million 55 
Geron Corporation  791,864.34 $ 204.301  Million 258 
Adma Biologics Inc   789,697.06 $ 510.934  Million 647 
Vericel Corporation  769,605.53 $ 306.303  Million 398 
Cerus Corporation  768,138.89 $ 221.224  Million 288 
Septerna Inc   760,630.77 $ 98.882  Million 130 
Dyadic International Inc   760,447.40 $ 3.802  Million 5 
Transmedics Group Inc   744,396.44 $ 668.468  Million 898 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.